Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study

This study aimed to prospectively evaluate, on a long-term basis, corneal side effects secondary to compassionate administration of epidermal growth factor receptor (EGFR) inhibitor depatuxizumab mafodotin (ABT-414) in patients affected by EGFR-amplified recurrent glioblastoma. Fifteen patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Parrozzani, Raffaele, Lombardi, Giuseppe, Midena, Edoardo, Londei, Davide, Padovan, Marta, Marchione, Giulia, Caccese, Mario, Midena, Giulia, Zagonel, Vittorina, Frizziero, Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591744/
https://www.ncbi.nlm.nih.gov/pubmed/33154952
http://dx.doi.org/10.3389/fonc.2020.593461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591744/
https://www.ncbi.nlm.nih.gov/pubmed/33154952
http://dx.doi.org/10.3389/fonc.2020.593461

Ejemplares similares